×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Osteoarthritis Market Size

ID: MRFR/Pharma/1078-HCR
90 Pages
Rahul Gotadki
October 2025

Osteoarthritis Market Research Report Information By Type (Hip Osteoarthritis, and Spinal Osteoarthritis), By Diagnosis (Imagining, and Joint Fluid Analysis), By Treatment (Medication, Surgery, Therapy), By End-User (Hospitals, and Medical Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Osteoarthritis Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Osteoarthritis Size

Osteoarthritis Market Growth Projections and Opportunities

With advances in technology, patients get better outcomes, which in turn impacts the market's growth. Examples include joint-preserving treatments, regenerative medicine, and minimally invasive surgery. Increasing obesity around the world puts stress on knees and is a major cause of osteoarthritis. When people put on weight, the joints that support their weight are put under more stress. This makes more people want treatments that will ease their symptoms and slow the disease's progress, which ultimately affects market trends. Growing use of biologics and disease-modifying osteoarthritis drugs (DMOADs) is another important market driver. Innovative drug methods try to change how a disease works at its core, giving people more options for managing pain and influencing the development of new therapies. Legal requirements and healthcare rules play a big role in shaping the osteoarthritis market. Therapies for osteoarthritis are safe and successful as long as they follow the rules set by officials. During the COVID-19 outbreak, market growth slowed down for a short time. Fewer new cases of osteoarthritis and stopped or pushed back treatment plans caused this. In June 2022, PubMed Central released a report that showed treatment for hip and fracture patients in the Czech Republic dropped a lot during the COVID-19 outbreak. It also brought up problems with the health care system, like the difference between care given outside of hospitals and care given in A&E. COVID-19 also slowed down the research and development work of pharmaceutical companies. It also slowed down the clinical testing of many new medicines around the world, including treatments for arthritis. This is why the COVID-19 spread quickly changed the market in a big way. More and more older people around the world are expected to have a big effect on the market that is being studied, since older people are more likely to get osteoarthritis. The UN says that by 2050, 16% of people will be 65 or older, up from 10% in 2022. A study from September 2022 on PubMed Central says that osteoarthritis is also a major cause of disability. More than 10% of people over 60 around the world have extraordinary arthritis. People who have osteoarthritis should think about how physical therapy and other types of rehabilitation can help them. As part of full-spectrum care, people with osteoarthritis can get non-drug treatments like physical therapy and exercise plans. These treatments change how the market makes choices. The market for medicines that help gout is also likely to grow. This is because better solutions are becoming available, more people are ready to go to therapy, and more people know about the disease. The Osteoarthritis Action Alliance says that May is Arthritis Awareness Month. It also said that osteoarthritis (OA) is the most common type of arthritis. Researchers also looked at a variety of tactics that people have used in the market. These include releasing new products, creating new products, joining with or buying other companies, making partnerships, and improving and adding to their product lines. The market that is being studied is likely to grow during the study term. There are many reasons for this, including more people becoming aware of osteoarthritis and new goods. The osteoarthritis treatment market might not grow as quickly as expected over the next few years, though, since hyaluronic acid products and other treatments are pricey and some of them have negative effects.

Osteoarthritis Market Size Graph
Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is the projected growth of the Osteoarthritis market?

The Osteoarthritis market is the expected increase in total market value of 13.37 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Osteoarthritis market?

Osteoarthritis market size was valued at approximately 5.12 billion USD in 2024. This figure will reach 13.37 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Osteoarthritis market?

Osteoarthritis market is expected to grow at a CAGR of 9.12% between 2025 and 2035.

How much will the Osteoarthritis market be worth by 2035?

Osteoarthritis market is expected to be worth of 13.37 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Osteoarthritis market perform over the next 10 years?

Over the next 10 years the Osteoarthritis market is expected to shift from usd billion 5.12 to 13.37 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region held the largest market share in the Osteoarthritis market?

North America had the largest share in the market

Who are the key players in the Osteoarthritis market?

The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.

Market Summary

As per MRFR analysis, the Osteoarthritis Market Size was estimated at 5.12 USD Billion in 2024. The Osteoarthritis industry is projected to grow from 5.58 USD Billion in 2025 to 13.37 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.12 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Osteoarthritis Market is experiencing transformative growth driven by innovative treatment approaches and demographic shifts.

  • The rise of biologics and regenerative medicine is reshaping treatment paradigms in the Osteoarthritis Market.
  • North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for osteoarthritis treatments.
  • Knee osteoarthritis continues to dominate the market, whereas hip osteoarthritis is witnessing the most rapid growth.
  • Key market drivers include the aging population and rising obesity rates, which are significantly influencing treatment demand.

Market Size & Forecast

2024 Market Size 5.12 (USD Billion)
2035 Market Size 13.37 (USD Billion)
CAGR (2025 - 2035) 9.12%
Largest Regional Market Share in 2024 North America

Major Players

<p>Pfizer (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Roche (CH)</p>

Market Trends

The Osteoarthritis Market is currently experiencing notable transformations driven by various factors. The increasing prevalence of osteoarthritis, particularly among the aging population, is prompting a surge in demand for effective treatment options. This market is characterized by a diverse range of therapies, including pharmaceuticals, physical therapies, and surgical interventions. Furthermore, advancements in technology are facilitating the development of innovative solutions, such as biologics and regenerative medicine, which may enhance patient outcomes. As healthcare systems evolve, there is a growing emphasis on personalized medicine, which could lead to tailored treatment plans that address individual patient needs. In addition to these developments, the Osteoarthritis Market is witnessing a shift towards preventive care and lifestyle modifications. Public awareness campaigns are likely to play a crucial role in educating individuals about the importance of maintaining joint health. Moreover, collaborations between pharmaceutical companies and research institutions are fostering the exploration of novel therapeutic approaches. This collaborative environment may accelerate the introduction of new products into the market, ultimately benefiting patients and healthcare providers alike. Overall, the Osteoarthritis Market appears poised for growth, driven by innovation and a focus on patient-centered care.

Rise of Biologics and Regenerative Medicine

The Osteoarthritis Market is increasingly embracing biologics and regenerative medicine as potential game-changers. These therapies aim to repair or regenerate damaged tissues, offering hope for improved joint function and reduced pain. As research progresses, the integration of these advanced treatments may redefine standard care practices.

Emphasis on Preventive Strategies

There is a growing focus on preventive strategies within the Osteoarthritis Market. Health professionals are advocating for lifestyle modifications, such as exercise and weight management, to mitigate the risk of developing osteoarthritis. This proactive approach may lead to better long-term outcomes for individuals at risk.

Personalized Medicine Initiatives

The trend towards personalized medicine is gaining traction in the Osteoarthritis Market. Tailoring treatment plans to individual patient profiles could enhance therapeutic efficacy and minimize adverse effects. This shift may represent a significant advancement in how osteoarthritis is managed, aligning treatments more closely with patient needs.

Osteoarthritis Market Market Drivers

Market Growth Projections

The Global Osteoarthritis Market Industry is poised for substantial growth, with projections indicating a market size of 5.12 USD Billion in 2024 and an anticipated increase to 13.4 USD Billion by 2035. This growth trajectory suggests a robust demand for osteoarthritis treatments and management solutions. The compound annual growth rate (CAGR) of 9.12% from 2025 to 2035 reflects the increasing recognition of osteoarthritis as a significant public health issue. As stakeholders in the healthcare sector respond to this demand, the market is likely to witness innovations and enhancements in treatment options, further solidifying its growth potential.

Growing Awareness and Education

The rising awareness and education surrounding osteoarthritis are crucial drivers of the Global Osteoarthritis Market Industry. Public health campaigns and educational initiatives are increasingly informing individuals about the disease, its risk factors, and management strategies. This heightened awareness encourages early diagnosis and treatment, which can lead to better health outcomes. Moreover, healthcare professionals are receiving enhanced training on osteoarthritis management, further promoting effective treatment options. As patients become more informed about their condition, they are more likely to seek medical advice and treatment, thereby driving market growth and fostering a proactive approach to managing osteoarthritis.

Increased Healthcare Expenditure

Growing healthcare expenditure across various regions is likely to bolster the Global Osteoarthritis Market Industry. As countries invest more in healthcare infrastructure and services, the availability and accessibility of osteoarthritis treatments improve. For instance, nations with higher healthcare budgets are more capable of funding advanced therapies and technologies. This trend is particularly evident in developed economies, where healthcare spending is projected to rise significantly in the coming years. The increased allocation of resources towards chronic disease management, including osteoarthritis, suggests a favorable environment for market expansion, potentially leading to a compound annual growth rate (CAGR) of 9.12% from 2025 to 2035.

Advancements in Treatment Options

Innovations in treatment modalities for osteoarthritis are propelling the Global Osteoarthritis Market Industry forward. Recent developments in pharmaceuticals, biologics, and regenerative medicine offer new avenues for managing symptoms and improving patient outcomes. For instance, the introduction of disease-modifying osteoarthritis drugs (DMOADs) aims to slow disease progression, which could alter the treatment landscape. Furthermore, minimally invasive surgical techniques are gaining traction, providing patients with effective alternatives to traditional surgery. These advancements not only enhance the quality of life for patients but also contribute to market growth, as healthcare providers seek to adopt the latest evidence-based practices.

Rising Prevalence of Osteoarthritis

The increasing prevalence of osteoarthritis globally is a primary driver of the Global Osteoarthritis Market Industry. As populations age, the incidence of osteoarthritis is expected to rise significantly. In 2024, the market is projected to reach 5.12 USD Billion, reflecting the growing need for effective treatments and management strategies. The World Health Organization indicates that osteoarthritis affects approximately 10% of the global population over 60 years, highlighting the urgency for innovative solutions. This trend is likely to continue, with projections suggesting that by 2035, the market could expand to 13.4 USD Billion, driven by the aging demographic and the associated healthcare demands.

Emerging Markets and Demographic Shifts

Emerging markets are becoming increasingly significant in the Global Osteoarthritis Market Industry due to demographic shifts and economic development. Countries in Asia-Pacific and Latin America are witnessing rapid urbanization and an increase in life expectancy, leading to a higher prevalence of osteoarthritis. As these regions develop economically, there is a growing demand for healthcare services and treatments. This trend is expected to create new opportunities for market players, as they seek to cater to the unique needs of these populations. The expansion into emerging markets could play a pivotal role in achieving the projected market growth, with a CAGR of 9.12% anticipated from 2025 to 2035.

Market Segment Insights

By Type of Osteoarthritis: Knee Osteoarthritis (Largest) vs. Hip Osteoarthritis (Fastest-Growing)

<p>The osteoarthritis market is significantly shaped by its different types, with Knee Osteoarthritis leading in market share among the segments. This dominance can be attributed to its high prevalence, especially among older demographics and those engaged in high-impact activities. Meanwhile, Hip Osteoarthritis is emerging as a fast-growing segment, driven by increasing incidence rates and rising awareness surrounding joint health. As the population ages, these market dynamics reflect a shifting focus towards effective management strategies.</p>

<p>Knee Osteoarthritis (Dominant) vs. Hip Osteoarthritis (Emerging)</p>

<p>Knee Osteoarthritis is the most prevalent type, largely impacting the quality of life and mobility for millions of sufferers. Its characteristics include pain primarily in the knee joint, stiffness, and swelling, which intensifies with physical activity. This segment benefits from various treatment options ranging from conservative management to surgical interventions, reflecting its dominant position. Conversely, Hip Osteoarthritis is gaining traction as an emerging segment, characterized by pain and stiffness in the hip joint, which can severely restrict movement. This segment's growth is supported by increased research investments, innovative therapies, and a greater emphasis on preventive care, making it a substantial area of focus for stakeholders in the osteoarthritis market.</p>

By Treatment Type: Pharmacological Treatment (Largest) vs. Non-Pharmacological Treatment (Fastest-Growing)

<p>In the Osteoarthritis Market, the treatment type segment is notably diverse, comprising pharmacological, non-pharmacological, surgical, and rehabilitation methods. Among these, pharmacological treatments command the largest market share due to their widespread usage and effective pain management capabilities. Non-pharmacological treatments are gaining traction rapidly, attributed to an increasing preference for holistic care approaches that emphasize lifestyle modifications and physical therapy.</p>

<p>Pharmacological Treatment (Dominant) vs. Non-Pharmacological Treatment (Emerging)</p>

<p>Pharmacological treatment is the dominant segment in the Osteoarthritis market, primarily comprising non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics, which provide relief to patients effectively. On the other hand, non-pharmacological treatment is emerging as a significant segment, focusing on therapies such as physiotherapy, acupuncture, and dietary management. This segment reflects a shift towards patient-centered care, emphasizing natural and lifestyle adjustments instead of relying solely on medication. As awareness of the benefits of these alternatives grows, the non-pharmacological treatment segment is expected to experience robust growth.</p>

By Severity Level: Moderate Osteoarthritis (Largest) vs. Severe Osteoarthritis (Fastest-Growing)

<p>In the Osteoarthritis Market, the distribution of market share among the severity levels reveals that Moderate Osteoarthritis holds the largest share. This segment is characterized by a significant number of patients managing chronic pain and requires ongoing treatment. Conversely, Severe Osteoarthritis, characterized by debilitating symptoms and limited mobility, has emerged as a growing segment due to increased awareness and diagnosis of severe conditions. With an aging population and rising obesity rates, these demographic factors contribute to this growth trajectory. Growth trends indicate that while Moderate Osteoarthritis remains stable in market dominance, Severe Osteoarthritis is gaining momentum as advancements in treatment options and patient management strategies evolve. The increasing prevalence of risk factors such as obesity and an aging demographic is propelling demand in this segment. Furthermore, innovative therapies and patient-centric care models are making severe treatment options more accessible, encouraging more patients to seek intervention, further boosting the segment’s growth.</p>

<p>Moderate Osteoarthritis (Dominant) vs. Severe Osteoarthritis (Emerging)</p>

<p>Moderate Osteoarthritis remains the dominant player in the severity level segment, comprising a substantial portion of the overall Osteoarthritis Market. This segment is characterized by symptoms such as joint pain, stiffness, and reduced range of motion, but patients often maintain a level of functionality, allowing for more conservative management options. On the other hand, Severe Osteoarthritis is emerging as a critical segment, driven by significant patient needs and treatment requirements. Patients in this group often experience chronic pain and functional limitations, necessitating more aggressive interventions such as surgical options and advanced therapeutic modalities. The divergence in treatment approaches for moderate and severe cases illustrates the evolving landscape of healthcare solutions available, shaped by patient demographics and treatment innovations.</p>

By Age Group: Older Adults (Largest) vs. Middle-Aged Adults (Fastest-Growing)

<p>The Osteoarthritis Market exhibits varying levels of prevalence across different age groups. Older Adults represent the largest share of the market, consistently exhibiting the highest incidence of osteoarthritis due to age-related wear and tear on joints. This demographic, typically aged 65 and above, contributes significantly to the demand for osteoarthritis treatments and management solutions as their need for pain relief and mobility enhancement continues to soar. In contrast, Middle-Aged Adults, particularly those between 45 and 64 years, showcase an increasing trend in the market as they increasingly suffer from osteoarthritis symptoms attributed to lifestyle factors, obesity, and previous joint injuries. The growth trends in the Osteoarthritis Market demonstrate a notable surge, particularly in the Middle-Aged Adults segment, which is becoming increasingly recognized as a crucial early-stage demographic for osteoarthritis treatment. This age group is driving growth as more individuals seek proactive management solutions to mitigate symptoms before they worsen. Factors fueling this upward trend include heightened awareness about joint health, increased diagnosis rates, and a growing inclination towards preventive healthcare measures, which positions them as emerging players in this market landscape.</p>

<p>Older Adults: Dominant vs. Middle-Aged Adults: Emerging</p>

<p>The Older Adults segment in the Osteoarthritis Market is characterized by a high prevalence of arthritis, primarily driven by the natural aging process, which leads to a gradual degradation of joint tissues. This segment is often associated with chronic pain and reduced mobility, prompting a strong demand for medical interventions such as pharmaceutical treatments and physical therapy options. As the population ages, this segment remains dominant, shaping market trends and product offerings significantly. Conversely, Middle-Aged Adults are emerging as a vital segment in the market, influenced by lifestyle factors such as sedentary behavior and obesity, which are contributing to earlier onset of osteoarthritis symptoms. This group exhibits a proactive approach to joint care, often seeking new therapies and products that promote joint health, thus influencing market dynamics and pushing for innovations in treatment options.</p>

Get more detailed insights about Osteoarthritis Market Research Report – Forecast Till 2035

Regional Insights

North America : Market Leader in Osteoarthritis

North America is poised to maintain its leadership in the osteoarthritis market, holding a significant share of 2.56B in 2024. The region's growth is driven by an aging population, increasing obesity rates, and heightened awareness of osteoarthritis treatments. Regulatory support and advancements in medical technology further catalyze market expansion, with a focus on innovative therapies and patient-centric solutions. The competitive landscape is robust, featuring key players such as Pfizer, Johnson & Johnson, and AbbVie. The U.S. remains the largest market, supported by extensive healthcare infrastructure and research initiatives. Companies are investing in R&D to develop novel treatments, ensuring a dynamic market environment that addresses the evolving needs of patients.

Europe : Emerging Market Dynamics

Europe's osteoarthritis market is projected to reach 1.52B by 2025, driven by increasing healthcare expenditure and a growing elderly population. The region benefits from strong regulatory frameworks that encourage innovation in treatment options. Additionally, rising awareness about osteoarthritis management and preventive care is fueling demand for effective therapies. Leading countries such as Germany, France, and the UK are at the forefront of this market, with significant contributions from major pharmaceutical companies like Novartis and Sanofi. The competitive landscape is characterized by collaborations and partnerships aimed at enhancing treatment efficacy and patient outcomes. "The European Medicines Agency emphasizes the importance of innovative therapies in managing chronic conditions like osteoarthritis," European Medicines Agency.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific osteoarthritis market, valued at 0.88B, is experiencing rapid growth due to increasing urbanization, lifestyle changes, and a rising prevalence of obesity. Governments are implementing initiatives to improve healthcare access and promote awareness of osteoarthritis, which is expected to drive demand for effective treatments. Regulatory bodies are also focusing on streamlining approval processes for new therapies. Countries like China and Japan are leading the market, with significant investments in healthcare infrastructure and research. The presence of key players such as Amgen and GlaxoSmithKline enhances competition, fostering innovation in treatment options. The region's diverse population presents unique challenges and opportunities for tailored therapies.

Middle East and Africa : Emerging Healthcare Landscape

The Middle East and Africa (MEA) osteoarthritis market, valued at 0.16B, is gradually emerging as a focus area for healthcare investments. The region faces challenges such as limited access to healthcare and varying levels of awareness about osteoarthritis. However, increasing government initiatives aimed at improving healthcare infrastructure and patient education are driving market growth. Countries like South Africa and the UAE are witnessing a rise in healthcare spending, which is expected to enhance the availability of osteoarthritis treatments. The competitive landscape is evolving, with both local and international players seeking to establish a foothold in this underserved market. "The World Health Organization highlights the need for improved healthcare access in the region to address chronic diseases like osteoarthritis," World Health Organization.

Key Players and Competitive Insights

The Osteoarthritis Market is currently characterized by a dynamic competitive landscape, driven by an increasing prevalence of the condition and a growing demand for effective treatment options. Key players such as Pfizer (US), Johnson & Johnson (US), and AbbVie (US) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovative therapies and biologics. These companies are actively pursuing partnerships and collaborations to enhance their product pipelines, thereby shaping a competitive environment that emphasizes both innovation and market responsiveness.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Novartis (CH) and Amgen (US) suggests a trend towards consolidation, as these firms seek to strengthen their market positions through strategic acquisitions and collaborations.

In November 2025, Pfizer (US) announced a partnership with a leading biotechnology firm to co-develop a novel gene therapy aimed at osteoarthritis treatment. This strategic move is likely to enhance Pfizer's portfolio, positioning it at the forefront of innovative treatment options and potentially transforming patient outcomes in the long term. The collaboration underscores the importance of leveraging cutting-edge technology to address unmet medical needs in the osteoarthritis space.

In October 2025, Johnson & Johnson (US) launched a new digital health platform designed to support patients with osteoarthritis in managing their symptoms more effectively. This initiative reflects a growing trend towards digitalization in healthcare, enabling personalized treatment plans and improving patient engagement. By integrating technology into their offerings, Johnson & Johnson aims to differentiate itself in a competitive market increasingly focused on patient-centric solutions.

In September 2025, AbbVie (US) expanded its clinical trial program for a promising new biologic therapy targeting osteoarthritis. This expansion not only demonstrates AbbVie's commitment to advancing treatment options but also highlights the company's strategic focus on research and development. By investing in innovative therapies, AbbVie is likely to enhance its competitive edge and address the evolving needs of patients suffering from osteoarthritis.

As of December 2025, current competitive trends indicate a significant shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are increasingly shaping the landscape, fostering innovation and collaboration among key players. Looking ahead, competitive differentiation is expected to evolve, with a pronounced shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine market dynamics, emphasizing the importance of delivering high-quality, effective treatments that meet the needs of patients.

Key Companies in the Osteoarthritis Market market include

Industry Developments

Robexera, the first generic robenacoxib medication, will be available in 2023, according to Krka. It is intended to treat pain and inflammation brought on by soft tissue surgery and persistent osteoarthritis (OA) in dogs. A once-daily dosage schedule for Robexera, a COX2 NSAID formulation, provides anti-inflammatory pain relief2,3,4.  The medicine comes in the form of a chewable tablet with flavoring to make it easier for pet owners to administer. It comes in four strengths for ease of administering, and each pack includes a set of PIL sheets that can be converted into prescription envelopes, color-coded boxes, and perforated blisters.

The U.S. Food and Drug Administration (U.S. FDA) has granted Zydus Lifesciences final permission in 2023 to produce and distribute 50 mg/200 mcg and 75 mg/200 mcg of Misoprostol Delayed Release Tablets USP, as well as 0.5 mg and 1 mg of Varenicline tablets. Arthrotec Delayed-Release tablets are the reference listed drug (RLD) for Diclofenac Sodium and Misoprostol Delayed Release Tablets. These tablets are intended to treat rheumatoid arthritis and osteoarthritis in individuals who are at high risk of developing stomach or intestinal ulcers. According to Zydus, the medication would be produced at the group's Ahmedabad formulation manufacturing facility.

The product's annual sales in the United States were $13 million, according to the business, which cited IQVIA MAT March 2023 numbers.

September 2022: StemOne, the off-the-shelf cell therapy product by Alkem Laboratories, received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. This product is being launched in collaboration with Stempeutics, which aims to treat knee osteoarthritis, a degenerative joint disease.

August 2022: Shionogi & Co., Ltd. and Grünenthal GmbH have entered into a licensing agreement to jointly market and commercialize injectable resiniferatoxin in Japan. Resiniferatoxin is a pipeline product developed by Grünenthal, and it is intended to treat pain caused by osteoarthritis of the knee. The licensing agreement will allow the companies to bring the product to market in Japan, offering a new treatment option for patients with knee osteoarthritis.

Future Outlook

Osteoarthritis Market Future Outlook

<p>The Osteoarthritis Market is projected to grow at a 9.12% CAGR from 2024 to 2035, driven by increasing aging populations, rising obesity rates, and advancements in treatment options.</p>

New opportunities lie in:

  • <p>Development of personalized biologic therapies for osteoarthritis management.</p>
  • <p>Expansion of telehealth services for remote patient monitoring and consultations.</p>
  • <p>Investment in AI-driven diagnostic tools to enhance early detection and treatment planning.</p>

<p>By 2035, the Osteoarthritis Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient demand.</p>

Market Segmentation

Osteoarthritis Market Age Group Outlook

  • Young Adults
  • Middle-Aged Adults
  • Older Adults

Osteoarthritis Market Severity Level Outlook

  • Mild Osteoarthritis
  • Moderate Osteoarthritis
  • Severe Osteoarthritis

Osteoarthritis Market Treatment Type Outlook

  • Pharmacological Treatment
  • Non-Pharmacological Treatment
  • Surgical Treatment
  • Rehabilitation

Osteoarthritis Market Type of Osteoarthritis Outlook

  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Spinal Osteoarthritis

Report Scope

MARKET SIZE 20245.12(USD Billion)
MARKET SIZE 20255.58(USD Billion)
MARKET SIZE 203513.37(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)9.12% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledPfizer (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Roche (CH)
Segments CoveredType of Osteoarthritis, Treatment Type, Severity Level, Age Group
Key Market OpportunitiesAdvancements in personalized medicine and digital therapeutics enhance treatment options in the Osteoarthritis Market.
Key Market DynamicsRising demand for innovative therapies drives competitive forces and technological advancements in the Osteoarthritis Market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the projected growth of the Osteoarthritis market?

The Osteoarthritis market is the expected increase in total market value of 13.37 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Osteoarthritis market?

Osteoarthritis market size was valued at approximately 5.12 billion USD in 2024. This figure will reach 13.37 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Osteoarthritis market?

Osteoarthritis market is expected to grow at a CAGR of 9.12% between 2025 and 2035.

How much will the Osteoarthritis market be worth by 2035?

Osteoarthritis market is expected to be worth of 13.37 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Osteoarthritis market perform over the next 10 years?

Over the next 10 years the Osteoarthritis market is expected to shift from usd billion 5.12 to 13.37 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region held the largest market share in the Osteoarthritis market?

North America had the largest share in the market

Who are the key players in the Osteoarthritis market?

The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp &amp; Dohme Corp.

  1. Definition
    1. Scope of the Study
      1. Research Objective
      2. Assumptions
      3. Limitations
    2. Introduction
    3. Primary Research
    4. Secondary research
    5. Market Size Estimation
    6. Drivers
    7. Restrains
    8. Opportunities
    9. Challenges
    10. Macroeconomic Indicators
    11. Technology Trends & Assessment
    12. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
    13. Value Chain Analysis
    14. Investment Feasibility Analysis
    15. Pricing Analysis
  2. Chapter 6. Global Osteoarthritis Market, by Type
    1. Introduction
    2. Hip Osteoarthritis
    3. Market Estimates & Forecast, 2022-2030
    4. Wrist Osteoarthritis
    5. Market Estimates & Forecast, 2022-2030
    6. Spinal Osteoarthritis
    7. Market Estimates & Forecast, 2022-2030
    8. Others
  3. Chapter 7. Global Osteoarthritis Market, by Diagnosis
    1. Introduction
    2. Imaging
      1. X-rays
      2. Magnetic resonance imaging (MRI)
      3. Others
    3. Market Estimates & Forecast, 2022-2030
    4. Joint Fluid Analysis
      1. Market Estimates & Forecast, 2022-2030
    5. Others
  4. Chapter 8. Global Osteoarthritis Market, by Treatment
    1. Introduction
    2. Medication
      1. Analgesics
      2. Non-steroidal Anti-Inflammatory Drugs
    3. Market Estimates & Forecast, 2022-2030
    4. Market Estimates & Forecast, 2022-2030
    5. Market Estimates & Forecast, 2022-2030
    6. Therapies
    7. Market Estimates & Forecast, 2022-2030
    8. Surgery
    9. Market Estimates & Forecast, 2022-2030
    10. Others
  5. Chapter 9. Global Osteoarthritis Market, by End Users
    1. Introduction
    2. Hospitals & Clinics
    3. Market Estimates & Forecast, 2022-2030
    4. Medical Institutes
    5. Market Estimates & Forecast, 2022-2030
    6. Research Organization
    7. Market Estimates & Forecast, 2022-2030
    8. Others
  6. Chapter 10. Global Osteoarthritis Market, by Region
    1. Introduction
    2. America
      1. North America
      2. South America
    3. Europe
      1. Western Europe
      2. Eastern Europe
    4. Asia Pacific
      1. Japan
      2. China
      3. India
      4. Australia
      5. Republic of Korea
      6. Rest of Asia Pacific
    5. The Middle East & Africa
      1. United Arab Emirates
      2. Saudi Arabia
      3. Oman
      4. Kuwait
      5. Qatar
      6. Rest of the Middle East & Africa
    6. Chapter 11. Company Landscape
    7. Introduction
    8. Market Share Analysis
    9. Key Development & Strategies
      1. Key Developments
    10. Chapter 12 Company Profiles
    11. Abbott.
      1. Company Overview
      2. Product Overview
      3. Financials
      4. Key Developments
      5. SWOT Analysis
    12. Novartis AG
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Developments
      5. SWOT Analysis
    13. Pfizer Inc.
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Development
      5. SWOT Analysis
    14. Eli Lilly and Company.
      1. Company Overview
      2. Product/Business Segment Overview
      3. Financial Overview
      4. Key Development
      5. SWOT Analysis
    15. ABIOGEN PHARMA S.p.A
      1. Company Overview
      2. Product Overview
      3. Financial overview
      4. Key Developments
      5. SWOT Analysis
    16. Merck Sharp & Dohme Corp.
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Developments
      5. SWOT Analysis
    17. TissueGene Inc.
      1. Overview
      2. Product Overview
      3. Financials
      4. Key Developments
      5. SWOT Analysis
    18. Ampio Pharmaceuticals Inc.
      1. Overview
      2. Product Overview
      3. Financials
      4. Key Developments
      5. SWOT Analysis
    19. Regeneron
      1. Overview
      2. Product Overview
      3. Financials
      4. Key Developments
      5. SWOT Analysis
    20. Others
    21. Chapter 13 MRFR Conclusion
    22. Key Findings
      1. From CEO’s View Point
      2. Unmet Needs of the Market
    23. Key Companies to Watch
    24. Prediction of Osteoarthritis Market
    25. Chapter 14 Appendix
  7. LIST OF TABLES
  8. Osteoarthritis Industry Synopsis, 2022-2030
  9. Global Osteoarthritis Market Estimates and Forecast, 2022-2030, (USD Million)
  10. Global Osteoarthritis Market by Region, 2022-2030, (USD Million)
  11. Global Osteoarthritis Market by Type, 2022-2030, (USD Million)
  12. Global Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  13. Global Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  14. Global Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  15. North America Osteoarthritis Market by Type, 2022-2030, (USD Million)
  16. North America Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  17. North America Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  18. North America Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  19. U.S. Osteoarthritis Market by Type, 2022-2030, (USD Million)
  20. U.S. Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  21. U.S. Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  22. U.S. Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  23. Canada Osteoarthritis Market by Type, 2022-2030, (USD Million)
  24. Canada Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  25. Canada Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  26. Canada Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  27. South America Osteoarthritis Market by Type, 2022-2030, (USD Million)
  28. South America Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  29. South America Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  30. South America Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  31. Europe Osteoarthritis Market by Type, 2022-2030, (USD Million)
  32. Europe Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  33. Europe Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  34. Europe Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  35. Western Europe Osteoarthritis Market by Type, 2022-2030, (USD Million)
  36. Western Europe Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  37. Western Europe Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  38. Western Europe Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  39. Eastern Europe Osteoarthritis Market by Type, 2022-2030, (USD Million)
  40. Eastern Europe Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  41. Eastern Europe Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  42. Eastern Europe Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  43. Asia Pacific Osteoarthritis Market by Type, 2022-2030, (USD Million)
  44. Asia Pacific Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  45. Asia Pacific Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  46. Asia Pacific Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  47. Middle East & Africa Osteoarthritis Market by Type, 2022-2030, (USD Million)
  48. Middle East & Africa Osteoarthritis Market by Diagnosis, 2022-2030, (USD Million)
  49. Middle East & Africa Osteoarthritis Market by Treatment, 2022-2030, (USD Million)
  50. Middle East & Africa Osteoarthritis Market by End Users, 2022-2030, (USD Million)
  51. LIST OF FIGURES
  52. Research Process
  53. Segmentation for Global Osteoarthritis Market
  54. Market Dynamics for Global Osteoarthritis Market
  55. Global Osteoarthritis Market Share, by Type 2022
  56. Global Osteoarthritis Market Share, by Diagnosis 2022
  57. Global Osteoarthritis Market Share, by Treatment, 2022
  58. Global Osteoarthritis Market Share, by End Users, 2022
  59. Global Osteoarthritis Market Share, by Region, 2022
  60. North America Osteoarthritis Market Share, by Country, 2022
  61. Europe Osteoarthritis Market Share, by Country, 2022
  62. Asia Pacific Osteoarthritis Market Share, by Country, 2022
  63. Middle East & Africa Osteoarthritis Market Share, by Country, 2022
  64. Global Osteoarthritis Market: Company Share Analysis, 2022 (%)
  65. Abbott.: Key Financials
  66. Abbott.: Segmental Revenue
  67. Abbott.: Geographical Revenue
  68. Kinetec: Type UK Ltd: Key Financials
  69. Kinetec: Type UK Ltd: Segmental Revenue
  70. Kinetec: Type UK Ltd: Geographical Revenue
  71. Pfizer Inc.: Key Financials
  72. Pfizer Inc.: Segmental Revenue
  73. Pfizer Inc.: Geographical Revenue
  74. Eli Lilly and Company.: Key Financials
  75. Eli Lilly and Company.: Segmental Revenue
  76. Eli Lilly and Company.: Geographical Revenue
  77. ABIOGEN PHARMA S.p.A: Key Financials
  78. ABIOGEN PHARMA S.p.A: Segmental Revenue
  79. ABIOGEN PHARMA S.p.A: Geographical Revenue
  80. Merck Sharp & Dohme Corp.: Key Financials
  81. Merck Sharp & Dohme Corp.: Segmental Revenue
  82. Merck Sharp & Dohme Corp.: Geographical Revenue
  83. TissueGene Inc.: Key Financials
  84. TissueGene Inc.: Segmental Revenue
  85. TissueGene Inc.: Geographical Revenue
  86. Ampio Pharmaceuticals Inc.: Key Financials
  87. Ampio Pharmaceuticals Inc.: Segmental Revenue
  88. Ampio Pharmaceuticals Inc.:Geographical Revenue
  89. Regeneron: Key Financials
  90. Regeneron: Segmental Revenue
  91. Regeneron.: Geographical Revenue

Osteoarthritis Market Segmentation

Osteoarthritis Type Outlook (USD Billion, 2018-2030)

  • Hip Osteoarthritis
  • Spinal Osteoarthritis

Osteoarthritis Diagnosis Outlook (USD Billion, 2018-2030)

  • Imaging
  • Joint Fluid Analysis

Osteoarthritis Treatment Outlook (USD Billion, 2018-2030)

  • Medication
  • Surgery
  • Therapy

Osteoarthritis End User Outlook (USD Billion, 2018-2030)

  • Hospitals
  • Medical Institutes

Osteoarthritis Regional Outlook (USD Billion, 2018-2030)

  • North America Outlook (USD Billion, 2018-2030)
    • North America Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • North America Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • North America Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • North America Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • US Outlook (USD Billion, 2018-2030)
    • US Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • US Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • US Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • US Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • CANADA Outlook (USD Billion, 2018-2030)
    • CANADA Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • CANADA Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • CANADA Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • CANADA Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
  • Europe Outlook (USD Billion, 2018-2030)
  •  
    • Europe Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Europe Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Europe Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Europe Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Germany Outlook (USD Billion, 2018-2030)
    • Germany Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Germany Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Germany Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Germany Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • France Outlook (USD Billion, 2018-2030)
    • France Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • France Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • France Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • France Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • UK Outlook (USD Billion, 2018-2030)
    • UK Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • UK Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • UK Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • UK Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • ITALY Outlook (USD Billion, 2018-2030)
    • ITALY Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • ITALY Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • ITALY Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • ITALY Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • SPAIN Outlook (USD Billion, 2018-2030)
    • Spain Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Spain Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Spain Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Spain Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Rest Of Europe Outlook (USD Billion, 2018-2030)
    • Rest Of Europe Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • REST OF EUROPE Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • REST OF EUROPE Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • REST OF EUROPE Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
  • Asia-Pacific Outlook (USD Billion, 2018-2030)
  •  
    • Asia-Pacific Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Asia-Pacific Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Asia-Pacific Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Asia-Pacific Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • China Outlook (USD Billion, 2018-2030)
    • China Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • China Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • China Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • China Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Japan Outlook (USD Billion, 2018-2030)
    • Japan Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Japan Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Japan Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Japan Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • India Outlook (USD Billion, 2018-2030)
    • India Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • India Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • India Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
      • Others
    • India Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Australia Outlook (USD Billion, 2018-2030)
    • Australia Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Australia Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Australia Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Australia Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)
    • Rest of Asia-Pacific Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Rest of Asia-Pacific Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Rest of Asia-Pacific Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Rest of Asia-Pacific Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
  • Rest of the World Outlook (USD Billion, 2018-2030)
  •  
    • Rest of the World Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Rest of the World Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Rest of the World Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Rest of the World Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Middle East Outlook (USD Billion, 2018-2030)
    • Middle East Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Middle East Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Middle East Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Middle East Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Africa Outlook (USD Billion, 2018-2030)
    • Africa Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Africa Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Africa Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Africa Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
    • Latin America Outlook (USD Billion, 2018-2030)
    • Latin America Osteoarthritis by Type
      • Hip Osteoarthritis
      • Spinal Osteoarthritis
    • Latin America Osteoarthritis by Diagnosis 
      • Imaging
      • Joint Fluid Analysis
    • Latin America Osteoarthritis by Treatment
      • Medication
      • Surgery
      • Therapy
    • Latin America Osteoarthritis by End User
      • Hospitals
      • Medical Institutes
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓